1312 — Kontafarma China Holdings Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeMicro CapValue Trap

Annual income statement for Kontafarma China Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	803	894	809	898	915
Cost of Revenue
Gross Profit	396	506	471	516	514
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	824	989	838	982	1,359
Operating Profit	-20.9	-94.5	-28.7	-84.6	-444
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-54.5	-118	-43.9	-98	-455
Provision for Income Taxes
Net Income After Taxes	-56.3	-110	-61.1	-99	-483
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-15	-41.5	-28.8	-75.5	-428
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-15	-41.5	-28.8	-75.5	-428
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.007	-0.016	-0.018	-0.011	-0.049